Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Lung Cancer Lung Cancer—Non-Small Cell Metastatic

Lung Cancer—Non-Small Cell Metastatic

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
 
Shun Lu, Xiaorong Dong, Hong Jian, et al.
 Clinical trial information: NCT03849768
 
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
 
Suresh S. Ramalingam, Caicun Zhou, Tae Min Kim, et al.
Clinical trial information: NCT02716116
 
Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
 
Julien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Clinical trial information: NCT03845270
 
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
 
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Clinical trial information: NCT02477826
 
Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database.
 
William A. Stokes, Madhusmita Behera, Renjian Jiang, et al.
 
 
Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.
 
Biagio Ricciuti, Kathryn Cecilia Arbour, Joao Victor Machado Alessi, et al.
 
 
Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study. 
 
Lisa Derosa, Bertrand Routy, Laurence Zitvogel, et al.
Clinical trial information: NCT04567446
 
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
 
Juergen Wolf, Edward B. Garon, Harry J.M. Groen, et al.
Clinical trial information: NCT02414139
 
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with METamplification (METamp).
 
Xiuning Le, Luis G. Paz-Ares, Jan Van Meerbeeck, et al.
 Clinical trial information: NCT02864992
 
See also the following poster:
Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
 
Jyoti D. Patel, Xiuning Le, Remi Veillon, Ian Churchill Anderson, et al.
Clinical trial information: NCT02864992
 
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
 
Hiroshige Yoshioka, Toyoaki Hida, Hiroshi Nokihara,et al.
 Clinical trial information: 132316.
 
Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).
 
Rafal Dziadziuszko, Xiao Li, Eric C. Anderson, et al.
 Clinical trial information: NCT03178552
 
A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
 
Jonathan W. Riess, Mary Weber Redman, Paul Wheatley-Price, et al.
Clinical trial information: NCT03845296